|

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

RECRUITINGSponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
SponsorMemorial Sloan Kettering Cancer Center
Started2000-09-26
Est. completion2026-09
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT00588068

Summary

The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System

OR

* Clinically suspected neuroblastic tumors.

PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY):

PK Draw Inclusion Criteria

* Patients who receive naxitamab as part of their standard of care

Exclusion Criteria:

* None

Conditions2

CancerNeuroblastoma

Locations1 site

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Nai-Kong Cheung, M.D., Ph.D.

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.